European Symposium of Biopathology 2013 - Scientific program

(See also the 2012 Biopathology Symposium program of the previous edition - Videos included for 2013 attendants)
 
8h30 : Opening - Registration

9h00 :  Welcome adress (Jean-Christophe Fournet, Paris, France)

Session 1: Introduction: The co-developpement of companion diagnostics (CDx) and targeted therapy
9h05 :  Companion diagnostics and drug-diagnostic codevelopment (Jan Trøst Jørgensen, Fredensborg, Denmark)
9h30 : Indicators of the assessment of hospital-integrated tumor biobanks: main current stakes and bottlenecks (Paul Hofman, CHU Nice, France)
10h00: Molecular enrichment and targeted therapies development (Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France)

10H30:  Coffee Break

Session 2: Cancer Genome Interpretation: how to make it simple?
11h00: An introduction to the analysis of next-generation sequencing (NGS) of cancer genome (Dr Philippe Dessen, Institut Gustave Roussy, Villejuif, France)
11h20: Integrated Analysis and Interpretation of Variant and Gene Expression Data from Breast Cancer Subtypes (Jean-Noël Billaud, Nathan Pearson, Ingenuity / Qiagen, USA)
11h50: The SureCall NGS Data Workflow (Hervé Goidin, Agilent Technologies)
12h10: The Ampliseq / Ion reporter NGS Data Workflow (Xose Fernandez, Life Technologies)

12h30-13h30: Lunch
12h45:  Worklunch Affymetrix: Genomic profiling of non-small cell lung cancer with focus on metastasizing potential: 
Results from a prospective cohort study by Dietmar Pfeiffer (About the FFPE Oncoscan Plateform) (Registration required at info@symposium-biopathology.eu)
13h30 :  Exhibition visit

Session 3: Cancer updates
14h00 :  Germline and somatic DNA polymerase mutations drive colorectal and endometrial carcinogenesis
(Ian Tomlinson, University of Oxford, UK)
14h30 :  Biomarkers in breast cancer (Anne Vincent-Salomon, Institut Curie, Paris)
15h00 :  Biomarkers in malignant melanoma and melanocytic nevi. (Paolo A. Ascierto, Naples, Italy)
15h30 :  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. (Muhammed Murtaza, University of Cambridge, UK)

16H00 : Coffee break

Session 4: Circulating cell-free tumoral DNA: a new frontier in molecular pathology
16h30 : Introduction to the study of circulating tumor DNA and applications in breast cancer (Heidi Schwarzenbach, Institut für Tumorbiologie, Hamburg)
17h00 : Circulating tumor DNA: role in the study of response to targeted therapies in colorectal cancer  (Pierre Laurent-Puig, HEGP, Paris)
17h20 : Circulating tumor DNA in melanoma (Pamela Pinzani, Università di Firenze, Italy)
17h40 : Urine cell-free DNA as a marker of early prostate and bladder cancers (Valentina Casadio, IRCCS IRST, Meldola, Italy)
18h00 : Detection of chromosomal alterations in the circulation of cancer patients by whole-genome
sequencing (Mark Sausen, Personal Genome Diagnostics, USA)

18h20 : End of Day 1




javascript:rte('article', '97')

8h30 : Opening

Session 5: Molecular biology pipeline for clinical diagnosis (Chairperson: Dr Frédéric Bibeau)
9h00 :  Oncogenome sequencing: Cheaper, Faster, Surer (Dr Nicolas Sévenet, Bordeaux)
9h30 :  Targeted sequencing: how to choose the cancer gene panel ? (Dr Aude Lamy, Pr Jean-Christophe Sabourin, Rouen, France)
9h50 :  The integration of results for molecular pathology reporting. (Caris Life Sciences, USA)
10h10 : The French Ki-RAS network (Pr Jean-Christophe Sabourin, Rouen, France) 10h30-11h : Coffee Break

Session 6: Assessement of tissular biomarkers
11h00 : Automated assessment of morphological tissue biomarkers to advance drug and diagnostics development  (Florian Leiss, Definiens, Germany)
11h20 : The Immunoscore: a new prognostic parameter (Pr Paolo A. Ascierto, Naples, Italy)
11h40 :  Computed Tomography for 2D and 3D digital imaging for cancer assessment (Fabrice  Harms, LLTech-Institut Langevin, Paris, France)
12h00 :  Quantitative Proteomics of Colorectal cancer from microdissected FFPE-material to a depth >10000 proteins (Jacek R. Wisniewski, Max-Planck Institute of Biochemistry, Martinsried, Germany)

12h30-13h30: Lunch

12h45:  Worklunch NanoString: Analyzing Gene Expression miRNA and CNV Biomarkers from FFPE Tissues with the nCounter by Jim White (Registration required at info@symposium-biopathology.eu)

13h30 :  Exhibition visit

Session 7: Miscellaneous applications of DNA sequencing
14h00 :  Validation of forensic techniques by using archaeological material: biopathology (royal) examples (Dr Philippe Charlier, Hôpital Raymond Poincaré, Garches)
14h20 :  PathoDIsc: Identification of new infectious agents by NGS (Marc Eloit, Institut Pasteur, France)
14h40 :  The study of fetal DNA in maternal plasma 
15h00 :  How to manage low DNA quantity or quality (John Langmore, CSO, Rubicon Genomics, MI, USA)

Session 8: Discovering of new biomarkers and companion diagnostics (CDx) for cancer treatment
15h20 : Development of Two Companion Diagnostics (CDx) for a Therapeutic Vaccine for Lung Cancer (Philippe Ancian, Transgene, Strasbourg, France)
15h40 : Discovering robust multimarker signatures – pitfalls and best practices (Mariana Kuras, Ariana Pharma, Paris, France)
16h00 :  Automated information extraction for cancer knowledge (Luca Dini, CELI, France)
16h20 :  Predictive Biomarkers for cancer treatment (Fabien Calvo, InCA, Paris, France)
16h40 :  Conclusion
16h45 : End of the symposium

(See also the 2012 Biopathology Symposium program of the previous edition - with videos for 2013 attendants)